Literature DB >> 33684494

Subepithelial autoimmune bullous dermatoses disease activity assessment and therapy.

Carmen M Montagnon1, Julia S Lehman2, Dedee F Murrell3, Michael J Camilleri2, Stanislav N Tolkachjov4.   

Abstract

Subepidermal (subepithelial) autoimmune blistering dermatoses are a group of rare skin disorders characterized by the disruption of the dermal-epidermal junction through the action of autoantibodies. The fourth article in this continuing medical education series presents the current validated disease activity scoring systems, serologic parameters, treatments, and clinical trials for bullous pemphigoid, mucous membrane pemphigoid, epidermolysis bullosa acquisita, bullous systemic lupus erythematosus, anti-p200 pemphigoid, linear IgA bullous dermatosis, and dermatitis herpetiformis.
Copyright © 2021 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  anti-p200 pemphigoid; autoimmune blistering disease severity index system; autoimmune bullous disease quality of life; bullous pemphigoid; bullous pemphigoid disease area index; bullous systemic lupus erythematosus; dapsone; dermatitis herpetiformis; epidermolysis bullosa acquisita; linear IgA bullous dermatosis; mucous membrane pemphigoid; subepithelial autoimmune bullous dermatoses

Year:  2021        PMID: 33684494     DOI: 10.1016/j.jaad.2020.05.161

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  2 in total

1.  Case Report: Mucous Membrane Pemphigoid With IgG and IgA Anti-Laminin γ1 Antibodies and IgA Anti-Laminin α5 Antibodies.

Authors:  Wenjing Kuang; Hua Qian; Qiyue Zhang; Wei Li; Takashi Hashimoto; Xin Zeng; Xiaoguang Li
Journal:  Front Immunol       Date:  2022-06-01       Impact factor: 8.786

2.  Annular bullous pemphigoid: A case report and review of literature.

Authors:  Steffie Arès; Darosa Lim; Sungmi Jung; Danielle Bouffard; Alexandra Mereniuk
Journal:  SAGE Open Med Case Rep       Date:  2022-04-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.